



**BUSINESS & FINANCIAL UPDATE**

**Q2 and H1 2022**

September 13, 2022

# Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma S.A., including estimates of target market opportunity, timing of planned clinical trials and results from those trials, regulatory strategy and timing of planned regulatory submissions, manufacturing capabilities and strategy for expansion of the ERYCAPS platform. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimates based upon the information available to ERYTECH Pharma S.A. as of the date of this presentation. The company's expectations regarding the effects of COVID-19 on the Company's trials and development may be incorrect. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements. Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statement.



# Business & Financial Update Q2 & H1 2022

## Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer

## Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

## Questions & Answers

- Gil Beyen, Chief Executive Officer
- Eric Soyer, Chief Financial & Chief Operating Officer
- Iman El Hariry, MD, PhD, Chief Medical Officer

# ERYTECH, Leader in Red Blood Cell-based Therapeutics



Clinical stage biopharmaceutical company, founded in 2004 around its proprietary ERYCAPS® technology allowing reproducible encapsulation of therapeutics in red blood cells (RBC)



Proof of concept established with eryaspase (Graspa®), L-asparaginase encapsulated in donor derived RBC. Eryaspase demonstrated safety and efficacy in clinical trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer (PAC); development not further pursued following Phase 3 trial in 2L PAC not achieving primary endpoint and regulatory hurdles for ALL



Pipeline of preclinical programs with ERYCAPS® platform, including new development with RBC-derived extracellular vesicles (ERYCEV™)

Partnership with SQZ Biotech for immuno-modulation approach with RBC



Industrialized production: company operated cGMP facility in Lyon, France and long-term supply agreement with Catalent for North-America



HQ in Lyon, France; office in Cambridge, MA, US  
Listed on Nasdaq and Euronext (Ticker ERYP)  
Strategic partnering process ongoing



# Business Highlights Q2 2022

Catalent

- Princeton (NJ) cell therapy manufacturing facility sold to Catalent in April 2022 for a total consideration of USD 44.5 million; team of 40 transferred to Catalent

Graspa


- Plans to pursue a BLA submission for Graspa<sup>®</sup> in hypersensitive ALL stopped following recent feedbacks and new additional requests from the FDA

Trybeca-2

- No evidence of clinical benefit in TRYbeCA-2, Ph 2 clinical trial in triple-negative breast cancer (TNBC) in patients enrolled before early study closure



- Deep restructuring and cost reduction program ongoing



- Promising preclinical development with ERYCEV<sup>™</sup>, novel red blood cell vesiculation technology



- Good progress on strategic review and partnering alternatives



# Business & Financial Update Q2 & H1 2022

## Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer

## Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

## Questions & Answers

- Gil Beyen, Chief Executive Officer
- Eric Soyer, Chief Financial & Chief Operating Officer
- Iman El Hariry, MD, PhD, Chief Medical Officer

## Q2 and H1 2022 Financial Results – P&L

- Net loss for 1H 2022 was €1.0 million, a €27.0 million improvement year-over-year
  - €24.4 million net gain on the sale of the Princeton facility
  - €6.0 million (-19%) decrease in operating expenses
- Total operating expenses of €25.2 million included an asset impairment provision of €2.5 million on the Lyon production facility, with the end of eryaspase operations, and a €1.9 million provision for restructuring, related to the resizing of French operations and staff.
- Income tax included a provision of €3.7 million (\$4.1 million), reflecting the best estimate to date of the tax impacts of the capital gain from the sale of the Princeton facility.

<i>In thousands of euros</i>	<b>1H 2022</b> <b>(6 months)</b>	<b>1H 2021</b> <b>(6 months)</b>
Revenues	—	—
Other income	954	2,270
Net gain on asset sale	24,351	—
<b>Operating income</b>	<b>25,304</b>	<b>2,270</b>
Research and development	(17,300)	(23,208)
General and administrative	(7,911)	(8,027)
<b>Operating expenses</b>	<b>(25,211)</b>	<b>(31,235)</b>
<b>Operating income (loss)</b>	<b>93</b>	<b>(28,966)</b>
Financial income	3,370	2,807
Financial expenses	(750)	(1,791)
<b>Financial income (loss)</b>	<b>2,620</b>	<b>1,016</b>
Income tax	(3,737)	(2)
<b>Net loss</b>	<b>(1,024)</b>	<b>(27,952)</b>

# Q2 and H1 2022 Financial Results - Cash Position and Cash Runway

- As of June 30, 2022: total cash position of €53.3 million (\$ 55.8 million) compared with €33.7 million (\$38.1 million) on December 31, 2021
- The €19.6 million increase in cash position in the first half of 2022 was attributable to:
  - €37.6 million net cash inflow from the sale of the Princeton facility to Catalent for \$44.5 million
  - €20.4 million net cash utilization in operating and financing activities.
  - €2.0 million cash generated in financing activities
  - Positive \$/€ currency exchange impact of €0.4 million
- Earlier this year, the company initiated a deep restructuring and cost reduction program, now further intensified with the halt of the BLA process. Considering this ongoing reduction in operating expenses, the Company believes that its current cash position can fund its current programs and planned operating expenses to mid-2024.



# Key News Flow and Milestones Expected Over the Next 6 Months

- Results of Phase 1 IST rESPECT in 1L pancreatic cancer
- Update on strategic review and partnering process



# Business & Financial Update Q2 & H1 2022

## Introduction and Business Highlights


- Gil Beyen, Chief Executive Officer

## Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

## Questions & Answers

- Gil Beyen, Chief Executive Officer
- Eric Soyer, Chief Financial & Chief Operating Officer
- Iman El Hariry, MD, PhD, Chief Medical Officer



# Thank you!

ERYTECH Pharma SA  
60 Avenue Rockefeller  
69008 Lyon  
France

erytech 

 Nasdaq

**ERYP**  
**LISTED**  
EURONEXT

ERYTECH Pharma Inc  
1 Main Street  
Cambridge, MA 02142  
USA